Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Disc. 23, 656–657; 2024). With the ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm that the therapy is no longer a priority. The drug in question, formerly ...

Avinasi Labs Enables a New Funding & Revenue Model for Clinical Stage Assets via DeLong Protocol SAN FRANCISCO, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — Avinasi Labs, an AI-native ...

Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.